Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive NBI-1065845 for major depressive disorder
2024-519418-29-00Phase 3Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and persistent depressive disorder (PDD) comparing NBI-1065845 adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Change from baseline in total MADRS score at Day 56. Planned start Sep 2025; status: authorised.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on 2024-519418-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519418-29-00.